Cedilizumab is a monoclonal antibody that primarily targets the CD4 receptor on T cells, which plays a crucial role in the immune response. It is designed to modulate immune activity, particularly in the context of autoimmune diseases and organ transplantation. The substance is characterized by its ability to inhibit T cell activation and proliferation, thereby reducing the immune response. Cedilizumab has been investigated for its potential therapeutic applications in conditions such as rheumatoid arthritis and other inflammatory disorders. As a biologic agent, it is produced through recombinant DNA technology, which allows for the specific targeting of immune pathways. The safety and efficacy of cedilizumab, like other monoclonal antibodies, are typically assessed through clinical trials, focusing on its pharmacokinetics, potential side effects, and overall impact on disease progression. Its development reflects the growing trend in biopharmaceuticals aimed at precision medicine, targeting specific components of the immune system to achieve desired therapeutic outcomes.

Cedelizumab

156586-90-2: Cedilizumab is a monoclonal antibody that primarily targets the CD4 receptor on T cells, which plays a crucial role in the immune response. It is designed to modulate immune activity, particularly in the context of autoimmune diseases and organ transplantation. The substance is characterized by its ability to inhibit T cell activation and proliferation, thereby reducing the immune response. Cedilizumab has been investigated for its potential therapeutic applications in conditions such as rheumatoid arthritis and other inflammatory disorders. As a biologic agent, it is produced through recombinant DNA technology, which allows for the specific targeting of immune pathways. The safety and efficacy of cedilizumab, like other monoclonal antibodies, are typically assessed through clinical trials, focusing on its pharmacokinetics, potential side effects, and overall impact on disease progression. Its development reflects the growing trend in biopharmaceuticals aimed at precision medicine, targeting specific components of the immune system to achieve desired therapeutic outcomes.

Cedelizumab (RWJ 49004), an IgG4 monoclonal antibody, selectively targets CD4 and exhibits immunosuppressant properties [1].

<p>A recombinant human monoclonal targeting CD4.</p>

CAS 156586-90-2

Cedelizumab

Cedelizumab

Ref: TM-T82756

Cedelizumab

Ref: 3D-CLA1073